Handelsavisen
prelaunch
Companies ›Healthcare ›314130.KQ
31
314130.KQ — KOSDAQ Biotechnology & Medical Research

Genome&Company Inc

$6 630,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-218,9 %
ROE
-14,3 %
Net margin
-190,8 %
Debt / equity
0,47
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Genome&Company Inc is a biotechnology company focused on healthcare diagnostics, offering products and services related to genetic and genomic testing.

Business. Genome&Company Inc (314130.KQ) is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. It is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic presence are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-14,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 314130.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 314130.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Genome&Company Inc (314130.KQ) is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. It is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic presence are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Genome&Company Inc has a strong liquidity position, with cash and equivalents amounting to KRW 59,755,466,520, which is significantly higher than its short-term liabilities. The company's liquidity FPT (free cash flow to total liabilities) is not explicitly provided, but the current ratio of 3.27 indicates a robust ability to meet short-term obligations.

    The company's profitability is currently negative, with a return on equity of -14.27% and a return on assets of -5.15%. These figures are below the typical performance metrics for the biotechnology and medical research industry, which often prioritize long-term R&D investment over short-term profitability.

    Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the biotechnology industry is typically characterized by high R&D intensity and long development cycles, which may affect revenue predictability and diversification.

    Looking ahead, the company is expected to continue facing financial challenges, as indicated by its negative operating and net income. The outlook for the current fiscal year suggests a continuation of these trends, with no significant improvement in revenue or profitability expected in the near term.

    The company's risk profile is currently low in terms of liquidity and dilution. There are no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.47 suggests a conservative capital structure. However, the negative free cash flow of KRW -8,772,799,540 and operating cash flow of KRW -3,336,464,780 indicate ongoing cash outflows that could become a concern if not managed effectively.

    Recent events and filings do not show any significant changes in the company's financial or operational status. The company continues to operate with a focus on long-term R&D and product development, which is typical for firms in the biotechnology and medical research industry.

    Key takeaways
    • Genome&Company Inc has a strong liquidity position with a current ratio of 3.27.
    • The company is currently unprofitable, with a return on equity of -14.27% and a return on assets of -5.15%.
    • The company's capital structure is conservative, with a debt-to-equity ratio of 0.47.
    • There are no immediate liquidity or dilution risks, but the company is experiencing negative free and operating cash flows.
    • The company's financial outlook for the current fiscal year is not positive, with no significant improvement in revenue or profitability expected.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Net income improved 68% year-over-year to a loss of 6.4 billion KRW, signaling narrowing operational deficits.

    Operating margin of -2.19% exceeds the biotechnology cohort median of -2.56%, suggesting relatively better cost efficiency.

    Long-term debt decreased to 19.0 billion KRW from 32.0 billion KRW in FY-1, reducing leverage pressure.

    BEAR CASE · 4

    The company faces high credit risk, potentially limiting access to affordable financing for future operations.

    Net margin of -1.91% remains deeply negative, confirming the company has not yet achieved profitability.

    Debt-to-equity ratio of 0.47 places the company in the bottom quartile of its biotechnology cohort.

    Cash conversion of 0.41 ranks in the bottom quartile, highlighting inefficiencies in generating cash from operations.

    In focus — financials by report

    Valuation FY

    Market price
    $6 630,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $56.98B
    Net cashⓘ
    $33.06B
    Current ratioⓘ
    3.3
    Debt / equityⓘ
    0.5
    ROAⓘ
    -5.1%
    ROEⓘ
    -14.3%
    Cash conversionⓘ
    41.0%
    CapEx / revenueⓘ
    -45.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-218,9 %Below median
    Net Margin-190,8 %Below median
    ROE-14,3 %Above median
    Capex / Rev-45,8 %Below median
    D/E0,47Bottom quartile
    Cash Conv0,41Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Genome&Company Inc Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    314130.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage